Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting

Atea Pharmaceuticals ( (AVIR) ) has shared an update.

On June 20, 2025, Atea Pharmaceuticals held its 2025 Annual Meeting of Stockholders, with approximately 87.6% of the company’s common stock represented. During the meeting, Bruno Lucidi, Dr. Polly Murphy, and Dr. Bruce Polsky were elected as Class II directors, and the appointment of KPMG LLP as the independent auditor for 2025 was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis.

The most recent analyst rating on (AVIR) stock is a Hold with a $6.88 price target. To see the full list of analyst forecasts on Atea Pharmaceuticals stock, see the AVIR Stock Forecast page.

Spark’s Take on AVIR Stock

According to Spark, TipRanks’ AI Analyst, AVIR is a Neutral.

Atea Pharmaceuticals faces significant financial challenges with no current revenue and profitability issues, impacting its sustainability. However, its strong cash position provides a buffer, and the promising HCV program may offer future growth opportunities. Positive strategic moves and a strong financial outlook provide some optimism, but overall risks remain high due to the lack of revenue and technical indicators showing bearish sentiment.

To see Spark’s full report on AVIR stock, click here.

More about Atea Pharmaceuticals

Atea Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing antiviral therapeutics. The company is known for its work on treatments for viral infections, including those caused by RNA viruses.

Average Trading Volume: 414,929

Technical Sentiment Signal: Hold

Current Market Cap: $274.7M

See more insights into AVIR stock on TipRanks’ Stock Analysis page.